ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Physical examination and ultrasound
  • physical examination and x-ray
  • physical function
  • physical function and patient-reported outcome measures
  • physical function and physical impairment
  • physical function and physical therapy
  • physical function and primary care
  • physical function and prognostic factors
  • Physical function and psoriatic arthritis
  • physical function and quality of life
  • physical function and rheumatoid arthritis
  • physical function and rheumatoid arthritis (RA)
  • physical function and socioeconomic status
  • physical function and stress
  • physical function and systemic lupus erythematosus (SLE)
  • physical function and test
  • physical function and total joint replacement
  • physical impairment
  • physical impairment and performance
  • physical impairment and population studies
  • physical impairment and psoriatic arthritis
  • physical impairment and psychometric properties
  • physical impairment and quality of life
  • physical impairment and rheumatoid arthritis
  • physical impairment and rheumatoid arthritis (RA)
  • physical impairment and systemic lupus erythematosus (SLE)
  • physical inactivity
  • physical therapy
  • physical therapy and physical activity
  • physical therapy and pilot study
  • physical therapy and population studies
  • physical therapy and qualitative
  • physical therapy and quality of life
  • physical therapy and randomized trials
  • physical therapy and rehabilitation
  • physical therapy and rheumatoid arthritis (RA)
  • physical therapy and self-management
  • physical therapy and shoulder disorders
  • physical therapy and spondylarthropathy
  • physical therapy and surgery
  • physical therapy and systemic sclerosis
  • physical therapy and tai chi
  • physical therapy and technology
  • physical therapy and total joint replacement
  • Physician Assistant
  • Physician Assistant and nurse practitioners
  • physician data
  • physician data and psoriatic arthritis
  • physician data and questionnaires
  • physician data and remission
  • physician data and rheumatoid arthritis (RA)
  • physician data and rheumatologic practice
  • physician data and risk
  • physician data and systemic lupus erythematosus (SLE)
  • physician data and trend
  • physician data and women's health
  • Physician Global Assesment
  • Physician-Patient Interaction
  • physiotherapy
  • picu
  • pilocarpine and treatment
  • pilot study
  • pilot study and spondylarthropathy
  • pilot study and vasculitis
  • PIMS
  • pivotal and phase 3
  • PKPD modeling
  • placebo
  • placenta
  • placenta and pregnancy
  • Plain Film
  • Plaque Psoriasis and Psoriatic Arthritis
  • plasma cells
  • plasma cells and iga
  • plasma cells and proteinuria
  • plasma cells and rheumatoid arthritis
  • plasma cells and rheumatoid arthritis (RA)
  • plasma cells and scleroderma
  • plasma cells and signal transduction
  • plasma cells and systemic lupus erythematosus (SLE)
  • plasma cells and therapeutic targeting
  • plasma cells and tolerance
  • plasma cells and toll-like receptors
  • Plasmablasts
  • Plasmablasts and antibodies
  • Plasmablasts and biomarkers
  • Plasmablasts and clinical trials
  • Plasmablasts and rheumatoid arthritis (RA)
  • Plasmablasts and SLE
  • Plasmablasts and tertiary
  • Plasmablasts and vasculitis
  • Plasmablasts and Wegener's granulomatosis
  • plasmacytoid dendritic cells and Type I IFN
  • Plasticity
  • platelets
  • platelets and Pathophysiology
  • platelets and rheumatoid arthritis
  • platelets and rheumatoid arthritis (RA)
  • platelets and scleroderma
  • platelets and systemic lupus erythematosus (SLE)
  • platelets and systemic sclerosis
  • platelets and thrombosis
  • platelets and toll-like receptors
  • platelets and vasculitis
  • Pneumococcal
  • pneumococcal vaccine
  • pneumocystis and opportunistic infections
  • pneumonia
  • Point-of-Care
  • polyangiitis
  • Polyangiitis and pulmonary complications
  • Polyangiitis and pulmonary fibrosis
  • polyangiitis and rituximab
  • polyangiitis and vasculitis
  • Polyarteritis nodosa
  • polyarteritis nodosa and treatment options
  • polyarteritis nodosa and vasculitis
  • polyarthritis
  • polyarthritis and prognostic factors
  • polyarthritis and psoriatic arthritis
  • polyarthritis and remission
  • polyarthritis and rheumatoid arthritis (RA)
  • polyarthritis and treatment
  • Polyarthritis and viruses
  • Polychondritis
  • polychondritis and positron emission tomography (PET)
  • polychondritis and regulatory cells
  • polychondritis and statistical methods
  • polychondritis and therapy
  • polychondritis and tocilizumab
  • polychondritis and transcription factor
  • polychondritis and treatment
  • polychondritis and ultrasonography
  • polychondritis and vasculitis
  • polyfunctional T cells
  • Polyhedraloligomericsilsesquioxane
  • polymerase chain reaction (PCR) and resveratrol
  • polymerase chain reaction (PCR) and rheumatoid arthritis (RA)
  • polymerase chain reaction (PCR) and synovial fluid
  • polymerase chain reaction (PCR) and systemic lupus erythematosus (SLE)
  • polymerase chain reaction (PCR) and test
  • polymorphism
  • polymorphism and genetics
  • polymorphism and population studies
  • polymorphism and prognostic factors
  • polymorphism and proteomics
  • polymorphism and psoriasis
  • polymorphism and pulmonary complications
  • polymorphism and race/ethnicity
  • polymorphism and remission
  • polymorphism and rheumatoid arthritis
  • polymorphism and rheumatoid arthritis (RA)
  • polymorphism and spondylarthropathy
  • polymorphism and systemic lupus erythematosus (SLE)
  • polymorphism and systemic sclerosis
  • polymorphism and temporal arteritis
  • polymorphism and transcription factor
  • polymorphism and uric acid
  • polymorphism and uveitis
  • Polymorphism and vasculitis
  • polymyalgia rheumatica
  • Polymyalgia Rheumatica (PMR)
  • polymyalgia rheumatica and Diagnostic Tests
  • polymyalgia rheumatica and environmental factors
  • polymyalgia rheumatica and leukocytes
  • polymyalgia rheumatica and methotrexate (MTX)
  • polymyalgia rheumatica and population studies
  • polymyalgia rheumatica and positron emission tomography (PET)
  • polymyalgia rheumatica and prednisolone
  • Polymyalgia rheumatica and prognostic factors
  • polymyalgia rheumatica and registries
  • polymyalgia rheumatica and regulatory cells
  • polymyalgia rheumatica and remission
  • polymyalgia rheumatica and rheumatoid arthritis (RA)
  • polymyalgia rheumatica and risk assessment
  • polymyalgia rheumatica and tocilizumab
  • polymyalgia rheumatica and treatment
  • polymyalgia rheumatica and treatment options
  • polymyalgia rheumatica and ultrasonography
  • Polymyalgia rheumatica and ultrasound
  • polymyalgia rheumatica and vasculitis
  • Polymyalgia rhuematica
  • polymyalgia rhuematica and prognostic factors
  • polymyositis
  • polymyositis and polymyositis/dermatomyositis (PM/DM)
  • polymyositis and positron emission tomography (PET)
  • polymyositis and prognostic factors
  • polymyositis and registry
  • polymyositis and rehabilitation
  • polymyositis and risk assessment
  • polymyositis and rituximab
  • polymyositis and safety
  • polymyositis and signal transduction
  • polymyositis and Sjogren's syndrome
  • polymyositis and systemic sclerosis
  • polymyositis and therapeutic targeting
  • polymyositis and ultrasonography
  • Polymyositis/dermatomyositis (PM/DM)
  • polymyositis/dermatomyositis (PM/DM) and Idiopathic Inflammatory Myopathies (IIM)
  • polymyositis/dermatomyositis (PM/DM) and interstitial lung disease
  • First |
  • « Previous Page
  • 45
  • 46
  • 47
  • 48
  • 49
  • [50]
  • 51
  • 52
  • 53
  • 54
  • 55
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology